JUNO OTC, A WHOLLY-OWNED SUBSIDIARY OF LSL PHARMA GROUP, SIGNS BINDING TERM SHEET WITH INSTAPILL PRIVATE LIMITED TO SUPPLY PRIVATE LABEL LORATADINE 10 MG RDT IN CANADA

The commercial launch is planned for June 2027 subject to Health Canada approval

BOUCHERVILLE, QC, April 9, 2026 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL) ("LSL Pharma" or the "Company"), a Canadian integrated pharmaceutical company, today announced the signing of a binding term sheet with Instapill Private Limited (Instapill) for the supply of private label Loratadine 10 mg rapid dissolve tablets (RDT) to Canadian retailers. The product is bioequivalent to Claritin RDT and positions LSL Pharma in the large, recurring over-the-counter (OTC) allergy category, addressing strong and growing consumer demand. The Canadian OTC allergy category is estimated at $60 million and growing at 8% per year.